Antigen News and Research

RSS

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.

27 May 2011

iBioLaunch Platform successfully expresses hookworm-derived molecule for potential vaccine

iBio, Inc. today announced that its proprietary iBioLaunch Platform successfully expressed the hookworm-derived molecule known as NaAPR1M-74, which will be evaluated as a potential vaccine candidate for human hookworm disease.

26 May 2011

Recent advances in vaccine development for malaria, TB and HIV/AIDS

Collectively, malaria, TB & HIV/AIDS cause more than five million deaths per year - nearly the entire population of the state of Washington - and represent one of the world's major public health challenges as we move into the second decade of the 21st century.

26 May 2011

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

ImmunoCellular Therapeutics, Ltd today announced it will be presenting new data from the Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme.

25 May 2011

Analysis of Nubian-era mummies finds schistosomiasis spread from altering environment

Mummies from along the Nile are revealing how age-old irrigation techniques may have boosted the plague of schistosomiasis, a water-borne parasitic disease that infects an estimated 200 million people today.

24 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Stopping prostate cancer cells from 'bulking up' with nutrients blocks spread of disease

Cancer Research UK scientists have discovered that stopping prostate cancer cells from 'bulking up' with nutrients reduces the spread of the disease and tumour size, according to research published today in EMBO Journal.

21 May 2011

VIDAS TOXO IgG Avidity assay to test for recent Toxoplasma gondii infection receives FDA clearance

On May 18, the U.S. Food and Drug Administration cleared the first test to help determine whether a pregnant woman or a person with swollen lymph nodes testing positive for toxoplasmosis, sometimes known as cat scratch disease, developed the infection within the past four months.

20 May 2011

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

Cytheris SA and the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.

18 May 2011

Epstein-Barr virus might cause multiple sclerosis, study confirms

The Epstein-Barr (EVB) virus -belonging to the herpesviruses family, which also includes the herpes simplex virus and the cytomegalovirus- is one of the environmental factors that might cause multiple sclerosis, a condition affecting the central nervous system, which causes are unknown.

18 May 2011

New A+PSA assay more accurately detects prostate cancer

A new test for prostate cancer that measures levels of prostate specific antigen (PSA) as well as six specific antibodies found in the blood of men with the disease was more sensitive and more specific than the conventional PSA test used today, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

17 May 2011

Super-resolution microscopy technique reveals how and why cell's defenses fail against plague

Researchers at Sandia National Laboratories have developed a super-resolution microscopy technique that is answering long-held questions about exactly how and why a cell's defenses fail against some invaders, such as plague, while successfully fending off others like E.coli.

17 May 2011

Biocept's paper describes identification of different CTC phenotypes in cancer patients

Biocept, Inc., a privately-held laboratory testing company focused on the detection, enumeration and analysis of circulating tumor cells (CTCs) in cancer patients, today announced the publication of a paper describing the identification of different CTC phenotypes using its proprietary Cell Enrichment and Extraction platform.

12 May 2011

Prostrate cancer patients can benefit from new MRI-ultrasound fusion

Targeted biopsy, a major advance in prostate cancer diagnostics, was detailed by a UCLA team in the current issue of Urologic Oncology. The new technology fuses MRI with real-time 3D ultrasound, providing an exacting method to obtain biopsy specimens from suspicious areas in the prostate.

12 May 2011

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Neogenix Oncology is pleased to announce that it will be granted a European Patent relating to its NEO-301 antibody, to take effect beginning September 23, 2011.

12 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

FDA clears Meridian's new C. difficile immunoassay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration for a new Clostridium difficile immunoassay named Premier C. difficile GDH.

11 May 2011

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

Inhibitex, Inc., announced today that Pfizer Inc. presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine at the 21st European Congress of Clinical Microbiology and Infectious Diseases and 27th International Congress of Chemotherapy in Milan, Italy.

10 May 2011

Mathematical approach can make combination vaccines more affordable for developing countries

Combination vaccines for young children are commonly used in industrialized nations because they provide protection for multiple diseases in one single injection. However, combination vaccines are prohibitively expensive for developing countries and may not available until several years later, or when market prices are more affordable.

10 May 2011

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.

9 May 2011

Antigen News and Research

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

iBioLaunch Platform successfully expresses hookworm-derived molecule for potential vaccine

Recent advances in vaccine development for malaria, TB and HIV/AIDS

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

Analysis of Nubian-era mummies finds schistosomiasis spread from altering environment

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Stopping prostate cancer cells from 'bulking up' with nutrients blocks spread of disease

VIDAS TOXO IgG Avidity assay to test for recent Toxoplasma gondii infection receives FDA clearance

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

Epstein-Barr virus might cause multiple sclerosis, study confirms

New A+PSA assay more accurately detects prostate cancer

Super-resolution microscopy technique reveals how and why cell's defenses fail against plague

Biocept's paper describes identification of different CTC phenotypes in cancer patients

Prostrate cancer patients can benefit from new MRI-ultrasound fusion

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Inovio first quarter total revenue increases to $3.1 million for 2011

FDA clears Meridian's new C. difficile immunoassay

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

Mathematical approach can make combination vaccines more affordable for developing countries

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics